477 related articles for article (PubMed ID: 15583739)
1. Antiphospholipid antibodies and thrombosis: association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinemia in arterial thrombosis.
Kassis J; Neville C; Rauch J; Busque L; Chang ER; Joseph L; Le Comte M; Subang R; Fortin PR
Thromb Haemost; 2004 Dec; 92(6):1312-9. PubMed ID: 15583739
[TBL] [Abstract][Full Text] [Related]
2. Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-beta2-glycoprotein-I antibodies.
Viveros ME; Cabiedes J; Reyes E; Cabral AR
Rev Invest Clin; 2005; 57(4):563-71. PubMed ID: 16315641
[TBL] [Abstract][Full Text] [Related]
3. Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies.
Neville C; Rauch J; Kassis J; Chang ER; Joseph L; Le Comte M; Fortin PR
Thromb Haemost; 2003 Jul; 90(1):108-15. PubMed ID: 12876633
[TBL] [Abstract][Full Text] [Related]
4. Risk of thrombosis in patients with antiphospholipid antibodies and factor V Leiden mutation.
Pablos JL; Caliz RA; Carreira PE; Atsumi T; Serrano L; Amengual O; Santiago B; Khamashta MA; Hughes GR; Gomez-Reino JJ
J Rheumatol; 1999 Mar; 26(3):588-90. PubMed ID: 10090167
[TBL] [Abstract][Full Text] [Related]
5. Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus.
Demir S; Li J; Magder LS; Petri M
Rheumatology (Oxford); 2021 Aug; 60(8):3770-3777. PubMed ID: 33331921
[TBL] [Abstract][Full Text] [Related]
6. Factor V Leiden, prothrombin gene mutation, and thrombosis risk in patients with antiphospholipid antibodies.
Chopra N; Koren S; Greer WL; Fortin PR; Rauch J; Fortin I; Senécal JL; Docherty P; Hanly JG
J Rheumatol; 2002 Aug; 29(8):1683-8. PubMed ID: 12180730
[TBL] [Abstract][Full Text] [Related]
7. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients.
Tarr T; Lakos G; Bhattoa HP; Shoenfeld Y; Szegedi G; Kiss E
Lupus; 2007; 16(1):39-45. PubMed ID: 17283584
[TBL] [Abstract][Full Text] [Related]
8. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study.
Mustonen P; Lehtonen KV; Javela K; Puurunen M
Lupus; 2014 Dec; 23(14):1468-76. PubMed ID: 25164304
[TBL] [Abstract][Full Text] [Related]
9. Hypercoagulability resulting from opposite effects of lupus anticoagulants is associated strongly with thrombotic risk.
Lecompte T; Wahl D; Perret-Guillaume C; Hemker HC; Lacolley P; Regnault V
Haematologica; 2007 May; 92(5):714-5. PubMed ID: 17488705
[TBL] [Abstract][Full Text] [Related]
10. Factor V Leiden, antiphospholipid antibodies and thrombosis in systemic lupus erythematosus.
Fijnheer R; Horbach DA; Donders RC; Vilé H; von Oort E; Nieuwenhuis HK; Gmelig-Meijling FH; de Groot PG; Derksen RH
Thromb Haemost; 1996 Oct; 76(4):514-7. PubMed ID: 8902988
[TBL] [Abstract][Full Text] [Related]
11. Activated protein C resistance in antiphospholipid thrombosis syndrome.
Wu J; Zhou Z; Li X; Li X; Chen Y; Wang G; Wang Z
Chin Med J (Engl); 2000 Aug; 113(8):699-701. PubMed ID: 11776051
[TBL] [Abstract][Full Text] [Related]
12. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis.
Reynaud Q; Lega JC; Mismetti P; Chapelle C; Wahl D; Cathébras P; Laporte S
Autoimmun Rev; 2014 Jun; 13(6):595-608. PubMed ID: 24418303
[TBL] [Abstract][Full Text] [Related]
13. Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study.
Zuily S; Regnault V; Guillemin F; Kaminsky P; Rat AC; Lecompte T; Wahl D
Thromb Res; 2013 Jul; 132(1):e1-7. PubMed ID: 23676348
[TBL] [Abstract][Full Text] [Related]
14. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
Bertolaccini ML; Atsumi T; Escudero Contreras A; Khamashta MA; Hughes GR
J Rheumatol; 2001 Dec; 28(12):2637-43. PubMed ID: 11764209
[TBL] [Abstract][Full Text] [Related]
15. Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies.
Sanmarco M; Gayet S; Alessi MC; Audrain M; de Maistre E; Gris JC; de Groot PG; Hachulla E; Harlé JR; Sié P; Boffa MC
Thromb Haemost; 2007 Jun; 97(6):949-54. PubMed ID: 17549297
[TBL] [Abstract][Full Text] [Related]
16. Homocysteine and antiphospholipid antibodies in rheumatoid arthritis patients: relationships with thrombotic events.
Seriolo B; Fasciolo D; Sulli A; Cutolo M
Clin Exp Rheumatol; 2001; 19(5):561-4. PubMed ID: 11579716
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of antiphospholipid antibodies in Syrian patients with thrombosis.
Deeb A; Hamdoun S; Dababo K
Iran J Immunol; 2009 Sep; 6(3):154-9. PubMed ID: 19801789
[TBL] [Abstract][Full Text] [Related]
18. Antiphospholipid antibodies in neonates with stroke--a unique entity or variant of antiphospholipid syndrome?
Berkun Y; Simchen MJ; Strauss T; Menashcu S; Padeh S; Kenet G
Lupus; 2014 Sep; 23(10):986-93. PubMed ID: 24729280
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of acquired activated protein C resistance in patients with systemic lupus erythematosus.
Muñoz-Rodríguez FJ; Reverter JC; Font J; Tàssies D; Espinosa G; Cervera R; Carmona F; Balsch J; Ingelmo M; Ordinas A
Lupus; 2002; 11(11):730-5. PubMed ID: 12475003
[TBL] [Abstract][Full Text] [Related]
20. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies.
Horbach DA; van Oort E; Donders RC; Derksen RH; de Groot PG
Thromb Haemost; 1996 Dec; 76(6):916-24. PubMed ID: 8972011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
